(Exenatide is FDA approved as monotherapy for the management of T2DM.) Explicitly stated in the guideline for patients requiring dual or triple therapy, the AACE/ACE preferentially recommends the addition of a GLP-1 receptor agonist or a DPP-4 inhibitor (sitagliptin, saxagliptin), citing their efficacy and safety profiles as preferred agents over TZDs or sulfonylureas (SUs)
doi: 10.1038/s42255-018-0009-4
Net prices will be cut on schedule (NHI revisions), DTC pull is muted, and prescribers are conservative
If you consistently feel worse on injection days, schedule rest days or light activity (walking only) for those days
The full COA library for Omnix Peptides is available at /coa-lab-reports/
Standard shipping: $25 worldwide with full tracking 715 business days from our Suzhou warehouse, discreetly packaged